Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $122.73 USD
Change Today -1.14 / -0.92%
Volume 1.6M
MNK On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

mallinckrodt plc (MNK) Snapshot

Open
$124.58
Previous Close
$123.87
Day High
$125.27
Day Low
$121.85
52 Week High
03/23/15 - $134.26
52 Week Low
08/12/14 - $67.18
Market Cap
14.4B
Average Volume 10 Days
778.2K
EPS TTM
$3.49
Shares Outstanding
117.0M
EX-Date
--
P/E TM
35.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for MALLINCKRODT PLC (MNK)

mallinckrodt plc (MNK) Related Businessweek News

View More BusinessWeek News

mallinckrodt plc (MNK) Details

Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, including neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the management of spasticity of cerebral or spinal origin. It also offers generics and active pharmaceutical ingredients (API), such as hydrocodone and hydrocodone-containing tablets, oxycodone and oxycodone-containing tablets, and methylphenidate HCl extended-release tablets, as well as biologics, medicinal opioids, synthetic controlled substances, acetaminophen products, and other active ingredients. The Global Medical Imaging segment provides contrast media and delivery systems comprising ioversol and gadoversetamide injections for diagnostic imaging applications under the Optiray and Optimark brand names with pre-filled syringes and power injectors to the hospitals and imaging centers. It also offers nuclear imaging products consisting of technetium-99m generators under the Ultra-Technekow DTE brand; cold kits; and Octreoscan kits for localization of tumors. The company markets its products to physicians, pharmacists, pharmacy buyers, specialty pharmacies, radiologists, and radiology technicians, as well as distributes its products to drug wholesalers, retail pharmacy chains, hospital networks, ambulatory surgical centers, and governmental agencies; sells and distributes APIs directly or through distributors to other pharmaceutical companies; and markets and distributes nuclear imaging products to radiopharmacies and hospitals. Mallinckrodt Public Limited Company was incorporated in 2013 and is based in Dublin, Ireland.

5,500 Employees
Last Reported Date: 11/25/14

mallinckrodt plc (MNK) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $905.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $605.1K
Senior Vice President of Global Operations
Total Annual Compensation: $1.4M
Senior Vice President and President of US Spe...
Total Annual Compensation: $400.0K
Chief Strategy Officer and Senior Vice Presid...
Total Annual Compensation: $449.2K
Compensation as of Fiscal Year 2014.

mallinckrodt plc (MNK) Key Developments

Mallinckrodt plc Invests EUR 45 Million to Expand Operations in Ireland

Mallinckrodt plc has invested EUR 45 million to expand its operations in Dublin, Ireland. A new manufacturing facility and office building are to be located at College Business and Technology Park, Blanchardstown, Dublin 15. The development will provide 300 jobs during the two-year construction phase and 45 skilled full-time positions once the construction is completed. This significant capital investment brings Mallinckrodt Pharmaceuticals' investment in Ireland to more than EUR 165million over the past 22 years.

Mallinckrodt public limited company Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 02:40 PM

Mallinckrodt public limited company Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 02:40 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Cole Lannum, Senior Vice President of Investor Strategy and Investor Relations Officer, Mark Christopher Trudeau, Chief Executive Officer, President, Director and Member of Portfolio Committee.

Mallinckrodt public limited company Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 12:00 PM

Mallinckrodt public limited company Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 12:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Matthew K. Harbaugh, Chief Financial Officer and Senior Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNK:US $122.73 USD -1.14

MNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $46.44 USD -0.57
Endo International PLC $86.19 USD -1.44
Hospira Inc $89.42 USD +0.19
Lannett Co Inc $59.03 USD +0.99
Pacira Pharmaceuticals Inc/DE $58.70 USD -0.94
View Industry Companies
 

Industry Analysis

MNK

Industry Average

Valuation MNK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MALLINCKRODT PLC, please visit www.mallinckrodt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.